Previous studies have reported the association between the abnormal elevation of KDM6B and the overactivated nuclear factor-κb (NF-κb)/innate immunity pathway in human CD34+ hematopoietic stem cells of myelodysplastic syndrome14, the oncogenic role of KDM6B in regulating immune cell differentiation and the immunological responses in lymphoid malignancies15–17, and the oncogenic activity of KDM6B in NOTCH1-driven human T-cell acute lymphocytic leukemia (T-ALL)18. The gene discussed is NFKB1; the disease is T-cell acute lymphoblastic leukemia.